GlassScriptPhysician profile
Moonasar Rampertaap
NPI 1558439083
$109,166.81
in general payments reported to CMS, 2019-2025
31 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $20K · 2021: $20K · 2022: $3,602 · 2023: $1,780 · 2024: $1,441 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,797 · Travel and Lodging: $443 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.56 |
| Travel and Lodging | $442.98 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $58,534.33 | 2019-2024 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,689.51 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $8,693.97 | 2019-2024 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $1,767.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,650.21 | 2020-2025 | Glassia |
| Astrazeneca Pharmaceuticals LP | $1,249.76 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Genentech, INC. | $1,000.00 | 2021 | |
| Grifols USA, LLC | $673.65 | 2020-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $503.94 | 2024-2025 | Inspire |
| Genentech USA, INC. | $303.11 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $273.23 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $272.66 | 2019-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $202.08 | 2019-2024 | |
| Insmed, INC. | $192.56 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $171.13 | 2021-2024 | Nuzyra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $163.29 | 2019-2022 | |
| Harmony Biosciences LLC | $160.82 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $113.18 | 2022-2023 | Hetlioz |
| Amgen INC. | $107.95 | 2023 | Repatha |
| Genzyme Corporation | $101.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $72.05 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $61.84 | 2019-2021 | |
| Philips North America LLC | $61.27 | 2019-2023 | |
| Csl Behring | $31.25 | 2019-2020 | |
| Vapotherm INC | $23.37 | 2022 | |
| Ethicon INC. | $23.04 | 2022 | |
| Verona Pharma, INC. | $19.16 | 2025 | Ohtuvayre |
| Baxter Healthcare | $18.88 | 2024 | Hillrom - Monarch Airway Clearance System |
| Nabriva Therapeutics, Plc | $17.49 | 2022 | |
| Resmed Corp | $14.43 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moonasar Rampertaap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.